中华实验外科杂志
中華實驗外科雜誌
중화실험외과잡지
CHINESE JOURNAL OF EXPERIMENTAL SURGERY
2015年
5期
959-961
,共3页
姜鹏玲%尼杰%谷峰%李春艳%张敏%只向成
薑鵬玲%尼傑%穀峰%李春豔%張敏%隻嚮成
강붕령%니걸%곡봉%리춘염%장민%지향성
乳腺癌%新辅助化疗%药物敏感性%常用化疗药物%胶原凝胶包埋培养法体外药敏检测技术
乳腺癌%新輔助化療%藥物敏感性%常用化療藥物%膠原凝膠包埋培養法體外藥敏檢測技術
유선암%신보조화료%약물민감성%상용화료약물%효원응효포매배양법체외약민검측기술
Breast cancer%Neoadjuvant chemotherapy%Chemosensitivity%Routine chemotherapy drugs%Collagen gel droplet embedded culture-drug sensitivity test
目的 检测新辅助化疗前后乳腺癌对常用化疗药物敏感性的变化.方法 收集536例可手术的原发性乳腺癌的新鲜癌组织作为A组;选取同期行TAC方案(多西他赛75 mg/m2+吡柔比星45 mg/m2+环磷酰胺600 mg/m2,每3周1次)或TEC方案(多西他赛75 mg/m2+表柔比星75 mg/m2+环磷酰胺600 mg/m2,每3周1次)4 ～6周期新辅助化疗后未达到病理完全缓解(pCR)的114例乳腺癌的新鲜癌组织作为B组,采用胶原凝胶包埋培养法体外药敏检测技术(CD-DST)检测乳腺癌细胞对多西他赛(DOC)、吡柔比星(THP)、表柔比星(EPI)、长春瑞滨(NVB)及顺铂(CDDP)的敏感性.结果 A组药物的单药有效率分别为:DOC(46.5％)、EPI(42.9％)、THP(42.7％)、CDDP(42.5％)、NVB (34.0％).B组药物的单药有效率分别为:DOC(31.6％)、EPI(28.9％)、THP(32.5％)、CDDP(46.5％)、NVB(36.8％).新辅助化疗后,乳腺癌对DOC和蒽环类药物的敏感性降低(P＜0.05),对CDDP和NVB的敏感性呈现上升趋势,但差异无统计学意义(P＞0.05).结论 新辅助化疗后,乳腺癌对DOC和蒽环类药物产生耐药,对CDDP和NVB的敏感性具有上升趋势.
目的 檢測新輔助化療前後乳腺癌對常用化療藥物敏感性的變化.方法 收集536例可手術的原髮性乳腺癌的新鮮癌組織作為A組;選取同期行TAC方案(多西他賽75 mg/m2+吡柔比星45 mg/m2+環燐酰胺600 mg/m2,每3週1次)或TEC方案(多西他賽75 mg/m2+錶柔比星75 mg/m2+環燐酰胺600 mg/m2,每3週1次)4 ～6週期新輔助化療後未達到病理完全緩解(pCR)的114例乳腺癌的新鮮癌組織作為B組,採用膠原凝膠包埋培養法體外藥敏檢測技術(CD-DST)檢測乳腺癌細胞對多西他賽(DOC)、吡柔比星(THP)、錶柔比星(EPI)、長春瑞濱(NVB)及順鉑(CDDP)的敏感性.結果 A組藥物的單藥有效率分彆為:DOC(46.5％)、EPI(42.9％)、THP(42.7％)、CDDP(42.5％)、NVB (34.0％).B組藥物的單藥有效率分彆為:DOC(31.6％)、EPI(28.9％)、THP(32.5％)、CDDP(46.5％)、NVB(36.8％).新輔助化療後,乳腺癌對DOC和蒽環類藥物的敏感性降低(P＜0.05),對CDDP和NVB的敏感性呈現上升趨勢,但差異無統計學意義(P＞0.05).結論 新輔助化療後,乳腺癌對DOC和蒽環類藥物產生耐藥,對CDDP和NVB的敏感性具有上升趨勢.
목적 검측신보조화료전후유선암대상용화료약물민감성적변화.방법 수집536례가수술적원발성유선암적신선암조직작위A조;선취동기행TAC방안(다서타새75 mg/m2+필유비성45 mg/m2+배린선알600 mg/m2,매3주1차)혹TEC방안(다서타새75 mg/m2+표유비성75 mg/m2+배린선알600 mg/m2,매3주1차)4 ～6주기신보조화료후미체도병리완전완해(pCR)적114례유선암적신선암조직작위B조,채용효원응효포매배양법체외약민검측기술(CD-DST)검측유선암세포대다서타새(DOC)、필유비성(THP)、표유비성(EPI)、장춘서빈(NVB)급순박(CDDP)적민감성.결과 A조약물적단약유효솔분별위:DOC(46.5％)、EPI(42.9％)、THP(42.7％)、CDDP(42.5％)、NVB (34.0％).B조약물적단약유효솔분별위:DOC(31.6％)、EPI(28.9％)、THP(32.5％)、CDDP(46.5％)、NVB(36.8％).신보조화료후,유선암대DOC화은배류약물적민감성강저(P＜0.05),대CDDP화NVB적민감성정현상승추세,단차이무통계학의의(P＞0.05).결론 신보조화료후,유선암대DOC화은배류약물산생내약,대CDDP화NVB적민감성구유상승추세.
Objective To select optimal chemotherapy regimens for locally advanced breast cancer (LABC) pretreated with anthracyclines and taxanes so as to examine chemosensitivity of routine chemotherapy drugs by collagen gel droplet embedded culture-drug sensitivity test (CD-DST).Methods A total of 536 fresh operable phosphate buffer(PBS) samples were collected as group A,114 fresh LABC smples that do not meet pCR after 4-6 cycles TAC or TEC neoadjuvant chemotherapy was selected as group B.Chemosensitivity of culture breast cancer cells to docetaxel (DOC),epirubicin (EPI),pirarubicin (THP),vinorelbine (NVB) and cisplatin (CDDP) was examined by CD-DST.Results The single drug efficiency of chemotherapy drugs in group A is respectively DOC (46.5％),EPI (42.9％),THP (42.7％),CDDP (42.5％) and NVB (34.0％).The single drug efficiency of chemotherapy drugs in group B is respectively DOC (31.6％),EPI (28.9％),THP (32.5％),CDDP (46.5％) and NVB (36.8％).After neoadjuvant chemotherapy,the sensitivity of DOC and anthracyclines in breast cancer is declined (P ＜ 0.05),the sensitivity of CDDP and NVB is on the rise,but there was no significant difference (P ＞ 0.05).Conclusion After neoadjuvant chemotherapy,breast cancer is resistant to DOC and anthracyclines,and the sensitivity of CDDP and NVB has a rising trend.
